Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study

References

• CoiffierB. Diffuse large cell lymphoma. Curr Opin Oncol. 2001;13:325–334. doi:10.1097/00001622-200109000-0000311555708
   PubMed Web of Science ®Google Scholar
• CoiffierB, ThieblemontC, Van Den NesteE, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d’Etudes des lymphomes de l’Adulte. Blood. 2010;116:2040–2045. doi:10.1182/blood-2010-03-27624620548096
   PubMed Web of Science ®Google Scholar
• SarkozyC, SehnLH. Management of relapsed/refractory DLBCL. Best Pract Res Clin Haematol. 2018;31:209–216. doi:10.1016/j.beha.2018.07.01430213390
   PubMed Web of Science ®Google Scholar
• HunterBD, HerrM, MeachamPJ, et al. Late relapses after high-dose chemotherapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in the rituximab era. Clin Lymphoma Myeloma Leuk. 2017;17:145–151. doi:10.1016/j.clml.2016.11.00127998707
   PubMed Web of Science ®Google Scholar
• TillyH, Gomes da SilvaM, VitoloU, et al. Diffuse large b-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–v125. doi:10.1093/annonc/mdv30426314773
   PubMed Web of Science ®Google Scholar
• JorgensenJM, SorensenFB, BendixK, et al. Angiogenesis in non-Hodgkin’s lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma. 2007;48:584–595. doi:10.1080/1042819060108324117454603
   PubMed Web of Science ®Google Scholar
• MangiMH, NewlandAC. Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol. 2000;111:43–51. doi:10.1046/j.1365-2141.2000.02104.x11091181
   PubMed Web of Science ®Google Scholar
• LiJ, QinS, XuJ, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448–1454. doi:10.1200/JCO.2015.63.599526884585
   PubMed Web of Science ®Google Scholar
• LanCY, WangY, XiongY, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a Phase 2, single-arm, prospective study. Lancet Oncol. 2018;19:1239–1246. doi:10.1016/S1470-2045(18)30349-830082170
   PubMed Web of Science ®Google Scholar
• LiF, ZhuT, CaoB, WangJ, LiangL. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Eur J Cancer. 2017;84:184–192. doi:10.1016/j.ejca.2017.07.03728822888
   PubMed Web of Science ®Google Scholar
• HuX, ZhangJ, XuB, et al. Multicenter Phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135:1961–1969. doi:10.1002/ijc.2882924604288
   PubMed Web of Science ®Google Scholar
• ZhengK, XuM, WangL, YuX. Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases: a single-center observational study. Medicine (Baltimore). 2018;97:e11734. doi:10.1097/MD.000000000001173430075583
   PubMed Web of Science ®Google Scholar
• WangY, DengM, ChenQ, et al. Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway. Eur J Pharmacol. 2019;843:145–153. doi:10.1016/j.ejphar.2018.11.01230423319
   PubMed Web of Science ®Google Scholar
• LiL, XiaoS, ZhangL, et al. An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma. Oncotarget. 2018;9:16213–16219. doi:10.18632/oncotarget.2380629662638
   PubMedGoogle Scholar
• ChesonBD, PfistnerB, JuweidME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586. doi:10.1200/JCO.2006.09.240317242396
   PubMed Web of Science ®Google Scholar
• SimonR. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10. doi:10.1016/0197-2456(89)90015-92702835
   PubMedGoogle Scholar
• RamakrishnanV, TimmM, HaugJL, et al. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. Am J Hematol. 2012;87:277–283. doi:10.1002/ajh.2226322190165
   PubMed Web of Science ®Google Scholar
• OlssonAK, DimbergA, KreugerJ, Claesson-WelshL. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–371.16633338
   PubMed Web of Science ®Google Scholar
• AnsellSM, MinnemaMC, JohnsonP, et al. Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37:481–489. doi:10.1200/JCO.18.0076630620669
   PubMed Web of Science ®Google Scholar
• WilsonWH, YoungRM, SchmitzR, et al. Targeting b cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–926. doi:10.1038/nm.388426193343
   PubMed Web of Science ®Google Scholar
• DavidsMS, RobertsAW, SeymourJF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35:826–833. doi:10.1200/JCO.2016.70.432028095146
   PubMed Web of Science ®Google Scholar
• MorschhauserFA, CartronG, ThieblemontC, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2912–2919. doi:10.1200/JCO.2012.46.958523835718
   PubMed Web of Science ®Google Scholar
• CzuczmanMS, TrnenyM, DaviesA, et al. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2017;23:4127–4137. doi:10.1158/1078-0432.CCR-16-281828381416
   PubMed Web of Science ®Google Scholar
• NeelapuSS, LockeFL, BartlettNL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544. doi:10.1056/NEJMoa170744729226797
   PubMed Web of Science ®Google Scholar
• LenzG, HawkesE, VerhoefG, et al. Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2017;35:7536. doi:10.1200/JCO.2017.35.15_suppl.7536
   Web of Science ®Google Scholar
• Palanca-WesselsMC, CzuczmanM, SallesG, et al. Safety and activity of the anti-CD79b antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a Phase 1 study. Lancet Oncol. 2015;16:704–715. doi:10.1016/S1470-2045(15)70128-225925619
   PubMed Web of Science ®Google Scholar
• LiuZ, OuW, LiN, WangSY. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy. Thorac Cancer. 2018;9:1285–1290. doi:10.1111/1759-7714.1283630126078
   PubMed Web of Science ®Google Scholar
• FangSC, ZhangHT, ZhangYM, XieWP. Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma. Onco Targets Ther. 2017;10:447–452. doi:10.2147/OTT.S12661328176910
   PubMed Web of Science ®Google Scholar
• LiuX, QinS, WangZ, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017;10:153. doi:10.1186/s13045-017-0521-028870253
   PubMed Web of Science ®Google Scholar
• FangSC, HuangW, ZhangYM, ZhangHT, XieWP. Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib. Onco Targets Ther. 2019;12:985–992. doi:10.2147/OTT.S18998430774384
   PubMed Web of Science ®Google Scholar
• WuD, LiangL, NieL, et al. Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: apatinib treatment in nonsquamous NSCLC. Asia Pac J Clin Oncol. 2018;14:446–452. doi:10.1111/ajco.1287029573236
   PubMed Web of Science ®Google Scholar
• ParkJS, KimIK, HanS, et al. Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell. 2017;31:157–158. doi:10.1016/j.ccell.2016.12.00928073001
   PubMed Web of Science ®Google Scholar
• FukumuraD, KloepperJ, AmoozgarZ, DudaDG, JainRK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15:325–340. doi:10.1038/nrclinonc.2018.2929508855
   PubMed Web of Science ®Google Scholar
• HuW, FangJ, NieJ, et al. Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer. Medicine (Baltimore). 2016;95:e4183. doi:10.1097/MD.000000000000418327428214
   PubMed Web of Science ®Google Scholar
• ReckM, KaiserR, MellemgaardA, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a Phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143–155. doi:10.1016/S1470-2045(13)70586-224411639
   PubMed Web of Science ®Google Scholar
• SeymourJF, PfreundschuhM, TrnenyM, et al. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large b-cell lymphoma: final main study outcomes. Haematologica. 2014;99:1343–1349. doi:10.3324/haematol.2013.10081824895339
   PubMed Web of Science ®Google Scholar
• La VineDB, ColemanTA, DavisCH, CarbonellCE, DavisWB. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am J Clin Oncol. 2010;33:217–220. doi:10.1097/COC.0b013e3181a650a619745694
   PubMed Web of Science ®Google Scholar
• MiYJ, LiangYJ, HuangHB, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010;70:7981–7991. doi:10.1158/0008-5472.CAN-10-011120876799
   PubMed Web of Science ®Google Scholar
• KerbelRS. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell. 2005;8:269–271. doi:10.1016/j.ccr.2005.09.01616226701
   PubMed Web of Science ®Google Scholar